Why the study?
Does rivaroxaban improve antithrombotic efficacy compared to enoxaparin in patients undergoing total hip or knee arthroplasty?
Does rivaroxaban improve antithrombotic efficacy compared to enoxaparin in patients undergoing total hip or knee arthroplasty?
Rivaroxaban 10 mg daily is an effective and safe oral option for antithrombotic prophylaxis following major joint arthroplasty, demonstrating superior efficacy to enoxaparin.
May support rivaroxaban over enoxaparin post-arthroplasty; extends reviews but leaves RCT confirmation open.
The new oral, antithrombotic drug rivaroxaban is a direct factor Xa inhibitor, which can restrict thrombin generation both in vitro and in vivo. It has a predictable dose-dependent pharmacokinetic and pharmacodynamic profile and is well tolerated. In patients undergoing total hip or knee arthroplasty, rivaroxaban, 10 mg once daily started 6 - 8 h after the operation, had a significantly better antithrombotic efficacy and a comparable safety when compared with enoxaparin. Furthermore in all studies performed the drug had no adverse influence on the liver function in comparison with enoxaparin. In conclusion, rivaroxaban is a potent and safe new compound for antithrombotic prophylaxis in orthopaedic surgery.
No takes yet. Share an insight, caveat, or question.
Lars C. Borris (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: